{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36813923", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "05"}, "DateRevised": {"Year": "2023", "Month": "05", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "02", "Day": "23"}], "Language": ["eng"], "ELocationID": ["10.1038/s41418-023-01128-x"], "Journal": {"ISSN": "1476-5403", "JournalIssue": {"Volume": "30", "Issue": "4", "PubDate": {"Year": "2023", "Month": "Apr"}}, "Title": "Cell death and differentiation", "ISOAbbreviation": "Cell Death Differ"}, "ArticleTitle": "PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions.", "Pagination": {"StartPage": "1082", "EndPage": "1095", "MedlinePgn": "1082-1095"}, "Abstract": {"AbstractText": ["The VHL protein (pVHL) functions as a tumor suppressor by regulating the degradation or activation of protein substrates such as HIF1\u03b1 and Akt. In human cancers harboring wild-type VHL, the aberrant downregulation of pVHL is frequently detected and critically contributes to tumor progression. However, the underlying mechanism by which the stability of pVHL is deregulated in these cancers remains elusive. Here, we identify cyclin-dependent kinase 1 (CDK1) and peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) as two previously uncharacterized regulators of pVHL in multiple types of human cancers harboring wild-type VHL including triple-negative breast cancer (TNBC). PIN1 and CDK1 cooperatively modulate the protein turnover of pVHL, thereby conferring tumor growth, chemotherapeutic resistance and metastasis both in vitro and in vivo. Mechanistically, CDK1 directly phosphorylates pVHL at Ser80, which primes the recognition of pVHL by PIN1. PIN1 then binds to phosphorylated pVHL and facilitates the recruitment of the E3 ligase WSB1, therefore targeting pVHL for ubiquitination and degradation. Furthermore, the genetic ablation or pharmacological inhibition of CDK1 by RO-3306 and PIN1 by all-trans retinoic acid (ATRA), the standard care for Acute Promyelocytic Leukemia could markedly suppress tumor growth, metastasis and sensitize cancer cells to chemotherapeutic drugs in a pVHL dependent manner. The histological analyses show that PIN1 and CDK1 are highly expressed in TNBC samples, which negatively correlate with the expression of pVHL. Taken together, our findings reveal the previous unrecognized tumor-promoting function of CDK1/PIN1 axis through destabilizing pVHL and provide the preclinical evidence that targeting CDK1/PIN1 is an appealing strategy in the treatment of multiple cancers with wild-type VHL."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Chen", "ForeName": "Jiayi", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Li", "ForeName": "Mei", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China."}], "LastName": "Liu", "ForeName": "Yeqing", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Guan", "ForeName": "Tangming", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Yang", "ForeName": "Xiao", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Wen", "ForeName": "Yalei", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Zhu", "ForeName": "Yingjie", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, P. R. China."}], "LastName": "Xiao", "ForeName": "Zeyu", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmaceutic Sciences, Guizhou Medical University, University Town, Guiyang City and Guian New District, Guiyang, 550025, P. R. China."}], "LastName": "Shen", "ForeName": "Xiangchun", "Initials": "X"}, {"Identifier": ["0000-0002-0551-2916"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangdong Provincial Key Laboratory of Genome Stability and Disease Prevention, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518055, P. R. China. zhang.haoxing@szu.edu.cn."}], "LastName": "Zhang", "ForeName": "Haoxing", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Central Laboratory, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, P. R. China. tanghui085@jnu.edu.cn."}, {"Identifier": [], "Affiliation": "Department of Clinical Laboratory, The Fifth Affiliated Hospital of Jinan University Heyuan Shenhe People's Hospital, Heyuan, 517000, P. R. China. tanghui085@jnu.edu.cn."}], "LastName": "Tang", "ForeName": "Hui", "Initials": "H"}, {"Identifier": ["0000-0003-0859-3923"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, 510632, P. R. China. liutongzheng@jnu.edu.cn."}, {"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China. liutongzheng@jnu.edu.cn."}], "LastName": "Liu", "ForeName": "Tongzheng", "Initials": "T"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Cell Death Differ", "NlmUniqueID": "9437445", "ISSNLinking": "1350-9047"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "NIMA-Interacting Peptidylprolyl Isomerase"}, {"RegistryNumber": "EC 2.7.11.22", "NameOfSubstance": "CDC2 Protein Kinase"}, {"RegistryNumber": "EC 5.2.1.8", "NameOfSubstance": "Peptidylprolyl Isomerase"}, {"RegistryNumber": "5688UTC01R", "NameOfSubstance": "Tretinoin"}, {"RegistryNumber": "EC 5.2.1.8", "NameOfSubstance": "PIN1 protein, human"}, {"RegistryNumber": "EC 2.7.11.22", "NameOfSubstance": "CDK1 protein, human"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["genetics"], "DescriptorName": "NIMA-Interacting Peptidylprolyl Isomerase"}, {"QualifierName": ["genetics"], "DescriptorName": "CDC2 Protein Kinase"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Peptidylprolyl Isomerase"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tretinoin"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor\u2010negative, invasive breast cancer: The California Cancer Registry, 1999\u20132004. Cancer. 2008;112:737\u201347. doi: 10.1002/cncr.23243.", "ArticleIdList": ["10.1002/cncr.23243", "18189290"]}, {"Citation": "Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334. doi: 10.1158/1078-0432.CCR-06-3045.", "ArticleIdList": ["10.1158/1078-0432.CCR-06-3045", "17671126"]}, {"Citation": "Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol: Mech Dis. 2022;17:181\u2013204. doi: 10.1146/annurev-pathol-042420-093238.", "ArticleIdList": ["10.1146/annurev-pathol-042420-093238", "PMC9231507", "35073169"]}, {"Citation": "Nguyen HC, Yang H, Fribourgh JL, Wolfe LS, Xiong Y. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. Structure. 2015;23:441\u20139. doi: 10.1016/j.str.2014.12.014.", "ArticleIdList": ["10.1016/j.str.2014.12.014", "PMC4351159", "25661653"]}, {"Citation": "Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15:55\u201364. doi: 10.1038/nrc3844.", "ArticleIdList": ["10.1038/nrc3844", "25533676"]}, {"Citation": "Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018;361:290\u20135. doi: 10.1126/science.aap8411.", "ArticleIdList": ["10.1126/science.aap8411", "PMC6154478", "30026228"]}, {"Citation": "Liu X, Simon JM, Xie H, Hu L, Wang J, Zurlo G, et al. Genome-wide screening identifies SFMBT1 as an oncogenic driver in cancer with VHL loss. Mol Cell. 2020;77:1294\u2013306.e5. doi: 10.1016/j.molcel.2020.01.009.", "ArticleIdList": ["10.1016/j.molcel.2020.01.009", "PMC7093231", "32023483"]}, {"Citation": "Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, et al. pVHL suppresses kinase activity of Akt in a proline-hydroxylation\u2013dependent manner. Science. 2016;353:929\u201332. doi: 10.1126/science.aad5755.", "ArticleIdList": ["10.1126/science.aad5755", "PMC5326551", "27563096"]}, {"Citation": "Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-\u03baB agonist Card9 by CK2. Mol Cell. 2007;28:15\u201327. doi: 10.1016/j.molcel.2007.09.010.", "ArticleIdList": ["10.1016/j.molcel.2007.09.010", "PMC2128776", "17936701"]}, {"Citation": "Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991\u20135004. doi: 10.1200/JCO.2004.05.061.", "ArticleIdList": ["10.1200/JCO.2004.05.061", "15611513"]}, {"Citation": "Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002;34:58\u201368. doi: 10.1002/gcc.10054.", "ArticleIdList": ["10.1002/gcc.10054", "11921283"]}, {"Citation": "Ally A, Balasundaram M, Carlsen R, Chuah E, Clarke A, Dhalla N, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327\u201341.e23. doi: 10.1016/j.cell.2017.05.046.", "ArticleIdList": ["10.1016/j.cell.2017.05.046", "PMC5680778", "28622513"]}, {"Citation": "Miyakis S, Liloglou T, Kearney S, Xinarianos G, Spandidos DA, Field J. Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25\u201326 in non-small cell lung carcinomas. Lung Cancer. 2003;39:273\u20137. doi: 10.1016/S0169-5002(02)00506-8.", "ArticleIdList": ["10.1016/S0169-5002(02)00506-8", "12609565"]}, {"Citation": "Ampofo E, Kietzmann T, Zimmer A, Jakupovic M, Montenarh M, G\u00f6tz C. Phosphorylation of the von Hippel\u2013Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1\u03b1 mediated transcription. Int J Biochem Cell Biol. 2010;42:1729\u201335. doi: 10.1016/j.biocel.2010.07.008.", "ArticleIdList": ["10.1016/j.biocel.2010.07.008", "20637892"]}, {"Citation": "German P, Bai S, Liu X-D, Sun M, Zhou L, Kalra S, et al. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function. Oncogene. 2016;35:4973\u201380. doi: 10.1038/onc.2016.40.", "ArticleIdList": ["10.1038/onc.2016.40", "PMC5086402", "26973240"]}, {"Citation": "Kim JJ, Lee SB, Jang J, Yi S-Y, Kim S-H, Han S-A, et al. WSB1 promotes tumor metastasis by inducing pVHL degradation. Genes Dev. 2015;29:2244\u201357. doi: 10.1101/gad.268128.115.", "ArticleIdList": ["10.1101/gad.268128.115", "PMC4647558", "26545811"]}, {"Citation": "Liu X, Zhang X, Peng Z, Li C, Wang Z, Wang C, et al. Deubiquitylase OTUD6B governs pVHL stability in an enzyme\u2010independent manner and suppresses hepatocellular carcinoma metastasis. Adv Sci. 2020;7:1902040. doi: 10.1002/advs.201902040.", "ArticleIdList": ["10.1002/advs.201902040", "PMC7175249", "32328410"]}, {"Citation": "Miao Y, Han X, Zheng L, Xie Y, Mu Y, Yates JR, et al. Fimbrin phosphorylation by metaphase Cdk1 regulates actin cable dynamics in budding yeast. Nat Commun. 2016;7:1\u201312.. doi: 10.1038/ncomms11265.", "ArticleIdList": ["10.1038/ncomms11265", "PMC4832064", "27068241"]}, {"Citation": "Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang H-L, Hsu Y-H, et al. Blocking c-Met\u2013mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22:194\u2013201. doi: 10.1038/nm.4032.", "ArticleIdList": ["10.1038/nm.4032", "PMC4754671", "26779812"]}, {"Citation": "Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:1\u201312..", "ArticleIdList": ["PMC5228031", "28067227"]}, {"Citation": "Luo M-L, Zheng F, Chen W, Liang Z-M, Chandramouly G, Tan J, et al. Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition. Cancer Res. 2020;80:3033\u201345. doi: 10.1158/0008-5472.CAN-19-2739.", "ArticleIdList": ["10.1158/0008-5472.CAN-19-2739", "PMC7755124", "32193285"]}, {"Citation": "Heo J, Lee J, Nam YJ, Kim Y, Yun H, Lee S, et al. The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer. Exp Mol Med. 2022;54:801\u201311. doi: 10.1038/s12276-022-00786-0.", "ArticleIdList": ["10.1038/s12276-022-00786-0", "PMC9256744", "35729325"]}, {"Citation": "Liu S, Xie F, Gan L, Peng T, Xu X, Guo S, et al. Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation. Genomics. 2020;112:5343\u201355. doi: 10.1016/j.ygeno.2020.11.010.", "ArticleIdList": ["10.1016/j.ygeno.2020.11.010", "33189780"]}, {"Citation": "Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, et al. Hypoxia-inducible factor-2\u03b1 activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 2012;72:2285\u201393. doi: 10.1158/0008-5472.CAN-11-3836.", "ArticleIdList": ["10.1158/0008-5472.CAN-11-3836", "PMC3342485", "22419665"]}, {"Citation": "Kaelin WG., Jr The von Hippel\u2013Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8:865\u201373. doi: 10.1038/nrc2502.", "ArticleIdList": ["10.1038/nrc2502", "18923434"]}, {"Citation": "Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld J-U, et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science. 1997;278:1957\u201360. doi: 10.1126/science.278.5345.1957.", "ArticleIdList": ["10.1126/science.278.5345.1957", "9395400"]}, {"Citation": "Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111\u201321. doi: 10.1056/NEJMoa1300874.", "ArticleIdList": ["10.1056/NEJMoa1300874", "23841729"]}, {"Citation": "Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med. 2015;21:457\u201366. doi: 10.1038/nm.3839.", "ArticleIdList": ["10.1038/nm.3839", "PMC4425616", "25849135"]}, {"Citation": "Kozono S, Lin Y-M, Seo H-S, Pinch B, Lian X, Qiu C, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018;9:1\u201317. doi: 10.1038/s41467-018-05402-2.", "ArticleIdList": ["10.1038/s41467-018-05402-2", "PMC6085299", "30093655"]}, {"Citation": "Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818\u201322. doi: 10.1126/science.aax3769.", "ArticleIdList": ["10.1126/science.aax3769", "31727826"]}, {"Citation": "Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer. 2016;16:463\u201378. doi: 10.1038/nrc.2016.49.", "ArticleIdList": ["10.1038/nrc.2016.49", "27256007"]}, {"Citation": "Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271\u20135. doi: 10.1038/20459.", "ArticleIdList": ["10.1038/20459", "10353251"]}, {"Citation": "Weirich G, Klein B, W\u00f6hl T, Engelhardt D, Brauch H. VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endocrinol Metab. 2002;87:5241\u20136. doi: 10.1210/jc.2002-020651.", "ArticleIdList": ["10.1210/jc.2002-020651", "12414898"]}, {"Citation": "Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365:537\u201347. doi: 10.1056/NEJMra1011165.", "ArticleIdList": ["10.1056/NEJMra1011165", "21830968"]}, {"Citation": "Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012;487:380\u20134. doi: 10.1038/nature11207.", "ArticleIdList": ["10.1038/nature11207", "22801492"]}, {"Citation": "Keith B, Johnson RS, Simon MC. HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12:9\u201322. doi: 10.1038/nrc3183.", "ArticleIdList": ["10.1038/nrc3183", "PMC3401912", "22169972"]}, {"Citation": "Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 2007;8:904\u201316. doi: 10.1038/nrm2261.", "ArticleIdList": ["10.1038/nrm2261", "17878917"]}, {"Citation": "Edlich F, Fischer G. Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases. Molecular Chaperones in Health and Disease. 2006;172:359\u2013404.", "ArticleIdList": ["16610367"]}, {"Citation": "Yeh ES. Means ARPIN1 the cell cycle and cancer. Nat Rev Cancer. 2007;7:381\u20138. doi: 10.1038/nrc2107.", "ArticleIdList": ["10.1038/nrc2107", "17410202"]}, {"Citation": "Cheng C-W, Chow AK, Pang R, Fok EW, Kwong Y-L, Tse E. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin. Am J Pathol. 2013;182:765\u201375. doi: 10.1016/j.ajpath.2012.11.034.", "ArticleIdList": ["10.1016/j.ajpath.2012.11.034", "23333752"]}, {"Citation": "Shen Z-J, Esnault S, Schinzel A, Borner C, Malter JS. The peptidyl-prolyl isomerase Pin1 facilitates cytokine-induced survival of eosinophils by suppressing Bax activation. Nat Immunol. 2009;10:257\u201365. doi: 10.1038/ni.1697.", "ArticleIdList": ["10.1038/ni.1697", "PMC2847832", "19182807"]}, {"Citation": "Ryo A, Suizu F, Yoshida Y, Perrem K, Liou Y-C, Wulf G, et al. Regulation of NF-\u03baB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell. 2003;12:1413\u201326. doi: 10.1016/S1097-2765(03)00490-8.", "ArticleIdList": ["10.1016/S1097-2765(03)00490-8", "14690596"]}, {"Citation": "Ryo A, Nakamura M, Wulf G, Liou Y-C, Lu KP. Pin1 regulates turnover and subcellular localization of \u03b2-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001;3:793\u2013801. doi: 10.1038/ncb0901-793.", "ArticleIdList": ["10.1038/ncb0901-793", "11533658"]}, {"Citation": "Nakatsu Y, Yamamotoya T, Ueda K, Ono H, Inoue M-K, Matsunaga Y, et al. Prolyl isomerase Pin1 in metabolic reprogramming of cancer cells. Cancer Lett. 2020;470:106\u201314. doi: 10.1016/j.canlet.2019.10.043.", "ArticleIdList": ["10.1016/j.canlet.2019.10.043", "31678165"]}, {"Citation": "Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, et al. Prolyl\u2010isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med. 2014;6:99\u2013119. doi: 10.1002/emmm.201302909.", "ArticleIdList": ["10.1002/emmm.201302909", "PMC3936488", "24357640"]}, {"Citation": "Yuan W-C, Lee Y-R, Huang S-F, Lin Y-M, Chen T-Y, Chung H-C, et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011;20:214\u201328. doi: 10.1016/j.ccr.2011.07.008.", "ArticleIdList": ["10.1016/j.ccr.2011.07.008", "21840486"]}, {"Citation": "Santamar\u00eda D, Barri\u00e8re C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811\u20135. doi: 10.1038/nature06046.", "ArticleIdList": ["10.1038/nature06046", "17700700"]}, {"Citation": "Odle RI, Florey O, Ktistakis NT, Cook SJ. CDK1, the Other \u2018master regulator\u2019of autophagy. Trends Cell Biol. 2021;31:95\u2013107. doi: 10.1016/j.tcb.2020.11.001.", "ArticleIdList": ["10.1016/j.tcb.2020.11.001", "33272830"]}, {"Citation": "Haneke K, Schott J, Lindner D, Hollensen AK, Damgaard CK, Mongis C, et al. CDK1 couples proliferation with protein synthesis. J Cell Biol. 2020;219:e201906147. doi: 10.1083/jcb.201906147.", "ArticleIdList": ["10.1083/jcb.201906147", "PMC7054999", "32040547"]}, {"Citation": "Michowski W, Chick JM, Chu C, Kolodziejczyk A, Wang Y, Suski JM, et al. Cdk1 controls global epigenetic landscape in embryonic stem cells. Mol Cell. 2020;78:459\u201376.e13. doi: 10.1016/j.molcel.2020.03.010.", "ArticleIdList": ["10.1016/j.molcel.2020.03.010", "PMC7214218", "32240602"]}, {"Citation": "Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li Y-C, et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell. 2009;35:327\u201339. doi: 10.1016/j.molcel.2009.06.036.", "ArticleIdList": ["10.1016/j.molcel.2009.06.036", "PMC3024055", "19683496"]}, {"Citation": "Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17:280\u201392. doi: 10.1038/nrm.2016.27.", "ArticleIdList": ["10.1038/nrm.2016.27", "PMC4841706", "27033256"]}, {"Citation": "Kim S, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol. 2008;19:68\u201372. doi: 10.1093/annonc/mdm358.", "ArticleIdList": ["10.1093/annonc/mdm358", "17956886"]}, {"Citation": "Liu W-T, Wang Y, Zhang J, Ye F, Huang X-H, Li B, et al. A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma. Cancer Lett. 2018;425:43\u201353. doi: 10.1016/j.canlet.2018.03.043.", "ArticleIdList": ["10.1016/j.canlet.2018.03.043", "29608985"]}, {"Citation": "Sung W-W, Lin Y-M, Wu P-R, Yen H-H, Lai H-W, Su T-C, et al. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer. 2014;14:1\u20137. doi: 10.1186/1471-2407-14-951.", "ArticleIdList": ["10.1186/1471-2407-14-951", "PMC4302138", "25511643"]}, {"Citation": "Stauffer S, Zeng Y, Zhou J, Chen X, Chen Y, Dong J. CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. Cell Signal. 2017;39:74\u201383. doi: 10.1016/j.cellsig.2017.08.001.", "ArticleIdList": ["10.1016/j.cellsig.2017.08.001", "PMC5592141", "28780319"]}, {"Citation": "Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014;14:1\u201313. doi: 10.1186/1471-2407-14-32.", "ArticleIdList": ["10.1186/1471-2407-14-32", "PMC3903446", "24444383"]}, {"Citation": "Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Int J Oncol. 2014;44:735\u201344. doi: 10.3892/ijo.2013.2240.", "ArticleIdList": ["10.3892/ijo.2013.2240", "24378347"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "10", "Day": "21"}, {"Year": "2023", "Month": "2", "Day": "1"}, {"Year": "2023", "Month": "1", "Day": "20"}, {"Year": "2023", "Month": "4", "Day": "5", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "2", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "22", "Hour": "23", "Minute": "22"}, {"Year": "2023", "Month": "2", "Day": "23"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36813923", "PMC10070344", "10.1038/s41418-023-01128-x", "10.1038/s41418-023-01128-x"]}}], "PubmedBookArticle": []}